Among the most notable studies that will be made public are 'Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial'. Patients with recurrent platinum-sensitive small cell lung cancer (SCLC) who received a new dose of platinum immediately after lurbinectedin + doxorubicin showed improved survival compared to those who received it after topotecan/CAV, suggesting that Administration of lurbinectedin as a second line to patients with relapsed platinum-sensitive SCLC does not affect the efficacy of the subsequent platinum redose, and could prolong the platinum-free interval and improve patient survival.
'Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients'. These results suggest that lurbinectedin can effectively prolong the platinum-free interval while maintaining the ability to continue platinum-based therapy, leading to improved outcomes.
As part of the conclusion of the last two studies, Dr.
'Effectiveness and Safety Profile of Lurbinectedin in Second-
'Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis.' The study continues to enroll a broader population of SCLC patients than the Phase II clinical trial that supported FDA approval. The real-world safety profile of lurbinectedin in this analysis was generally consistent with that reported in the pooled trial, with no new safety signals. Prophylactic use of G-CSF likely contributed to the low rates of neutropenia reported.
Contact:
Tel: +34 91 846 6000
Fax: 91 846 6001
Email: pharmamar@pharmamar.com
(C) 2023 Electronic News Publishing, source